Interestingly, in a phase I clinical trial using H3B-8800 to treat myeloid malignancies (NCT02841540), aberrant expression of an alternatively spliced isoform of TMEM14C identified patients with good responses (Steensma et al, 2021). Here, TMEM14C is linked to myeloid neoplasm.